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Formation of microthrombi is a hallmark of acquired thromboticthrombocytopenic purpura. These microthrombi originate frominsufficient processing of ultra large von Willebrand factor multimers
by ADAMTS13 due to the development of anti-ADAMTS13 autoanti-
bodies. Several studies have identified the major histocompatibility com-
plex class II alleles HLA-DRB1*11, HLA-DQB1*03 and HLA-DQB1*02:02
as risk factors for acquired thrombotic thrombocytopenic purpura devel-
opment. Previous research in our department indicated that ADAMTS13
CUB2 domain-derived peptides FINVAPHAR and LIRDTHSLR are pre-
sented on HLA-DRB1*11 and HLA-DRB1*03, respectively. Here, we
describe the repertoire of ADAMTS13 peptides presented on HLA-DQ.
In parallel, the repertoire of ADAMTS13-derived peptides presented on
HLA-DR was monitored. Using HLA-DR- and HLA-DQ-specific antibod-
ies, we purified HLA/peptide complexes from ADAMTS13-pulsed
monocyte-derived dendritic cells. Using this approach, we identified
ADAMTS13-derived peptides presented on HLA-DR for all 9 samples
analyzed; ADAMTS13-derived peptides presented on HLA-DQ were
identified in 4 out of 9 samples. We were able to confirm the presentation
of the CUB2 domain-derived peptides FINVAPHAR and LIRDTHSLR on
HLA-DR. In total, 12 different core-peptide sequences were identified on
HLA-DR and 8 on HLA-DQ. For HLA-DR11, several potential new core-
peptides were found; 4 novel core-peptides were exclusively identified
on HLA-DQ. Furthermore, an in silico analysis was performed using the
EpiMatrix and JanusMatrix tools to evaluate the eluted peptides, in the
context of HLA-DR, for putative effector or regulatory T-cell responses at
the population level. The results from this study provide a basis for the
identification of immuno-dominant epitopes on ADAMTS13 involved in
the onset of acquired thrombotic thrombocytopenic purpura. 
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ABSTRACT
Introduction
Thrombotic thrombocytopenic purpura (TTP) is a severe life-threatening disor-
der caused by decreased levels of functional ADAMTS13 (a disintegrin and 
metalloproteinase with thrombospondin type 1 motifs, member 13). In healthy
individuals, ADAMTS13 regulates the size of von Willebrand Factor (VWF) multi-
mers through cleavage of a Tyr1605-Met1606 peptide
bond in the A2 domain of VWF.1,2 Functional or quantita-
tive defects in ADAMTS13 levels in the circulation lead to
the accumulation of high molecular weight VWF multi-
mers and the formation of platelet- and VWF-rich throm-
bi. Within the microvasculature, these thrombi cause
mechanical fragmentation of erythrocytes inducing
hemolytic anemia.1,2 In addition, the presence of hyper-
adhesive VWF multimers results in platelet consumption.
As a consequence, patients with TTP often present with
skin petechiae due to thrombocytopenia-induced blood
loss from small vessels in the skin.1,3 Additional clinical
symptoms may include fever, renal failure or neurological
abnormalities.1,2
In the majority of patients with TTP, the decrease in
ADAMTS13 levels is due to the development of autoanti-
bodies directed towards ADAMTS13. Most of these
autoantibodies are composed of IgG1 and IgG4 subclass-
es;4-6 these antibodies either inhibit the proteolytic func-
tion of ADAMTS13 or enhance its clearance from the cir-
culation.6-9 While the mechanisms responsible for the
development of anti-ADAMTS13 antibodies are currently
unknown, several reports have suggested that infections,
pregnancy or transplantation may be considered to be risk
factors for the onset of acquired TTP.10-12 The generation of
high affinity antibodies against ADAMTS13 is dependent
on the help of specific CD4+ T cells. Priming of antigen-
specific CD4+ T cells requires presentation of
ADAMTS13-derived peptides on major histocompatibili-
ty complex class II (MHC-II) on professional antigen pre-
senting cells.13 The MHC-II genes are highly polymorphic
allowing for the selection of a broad repertoire of CD4+ T
cells that is needed to combat infections. Specific MHC-II
alleles have been linked to autoimmune disorders such as
rheumatoid arthritis and celiac disease.14 Similarly, associ-
ation studies from three different cohorts of patients with
acquired TTP have identified HLA-DRB1*11 as a risk fac-
tor.15-17 Conversely, the frequency of HLA-DRB1*04 was
significantly lower in patients with acquired TTP, suggest-
ing a protective effect of this allele.15-17 In addition to 
HLA-DRB1*11, higher frequencies of alleles 
HLA-DQB1*0315,16 and HLA-DQB1*02:0217 were found in
patients with acquired TTP when compared to healthy
controls. A recent study of 190 Italian TTP patients and
1255 healthy controls suggested that HLA-DQB1*05:03
was less prevalent in patients with acquired TTP.18 This
study also proposed that the common single nucleotide
polymorphism rs6903608, which is located between the
genes encoding the alpha and beta5 chains of the HLA-DR
complex, combined with HLA-DQB1*05:03 explains most
of the observed association between the HLA locus and
acquired TTP.18 As yet, the molecular mechanism underly-
ing the observed association between polymorphic sites
within the MHC II locus and acquired TTP has not been
identified. 
Previous observation from our laboratory has shown
that monocyte-derived dendritic cells (mo-DCs) from
healthy donors preferentially presented two peptides
derived from the CUB2 domain of ADAMTS13.19 Both of
these peptides were found to activate CD4+ T cells of
patients with acquired TTP.20 In addition, CUB2 domain-
derived peptide ADAMTS131239-1253 was identified as an
immunodominant T-cell epitope in an HLA-DRB1 trans-
genic mouse model.21 The same study revealed that
ADAMTS131239-1253 reactive CD4+ T cells were present in
patients with acquired TTP as well as in peripheral blood
of healthy individuals.21 As yet, the presentation of
ADAMTS13-derived peptides on HLA-DQ has not been
investigated. In the present work, we aimed to define the
repertoire of ADAMTS13-derived peptides presented on
HLA-DQ and prospectively identify putative effector and
tolerated/tolerogenic T-cell epitopes using computational
tools (EpiMatrix and JanusMatrix). 
Methods
Materials
Recombinant full length ADAMTS13 was produced in stable
transfected HEK293 cells and purified as described previously.9
Concentration of purified ADAMTS13 was determined using the
Bradford assay. Lipopolysaccharide (LPS) was obtained from
Sigma-Aldrich (St. Louis, USA). The hybridoma producing the
HLA-DQ-specific antibody (SPV-L3)22 was a kind gift from Prof.
dr. H. Spits (Academic Medical Center, Amsterdam, the
Netherlands). The hybridoma producing the HLA-DR-specific
monoclonal antibody (L243) was purchased from ATCC (Wesel,
Germany). Antibodies were purified from culture supernatant via
protein A Sepharose (GE Healthcare) and coupled to CNBr
Sepharose 4B at a final concentration of 2 mg/mL (Amersham
Biosciences, Buckinghamshire, UK).
Endocytosis of ADAMTS13 and affinity purification of
HLA-DR and HLA-DQ
Monocytes were obtained from healthy volunteers in accor-
dance with Dutch regulations after approval from the Sanquin
Ethical Advisory Board, in accordance with the Declaration of
Helsinki. After five days of differentiation, 5x106 immature mo-
DCs were incubated with 100 nM of recombinant ADAMTS13 in
Cellgro medium supplemented with 800 U/ml IL-4 and 1000
U/mL GM-CSF. After five hours of incubation, the medium was
supplemented without washing with 1 mg/mL of LPS and 1% fetal
calf serum to allow for mo-DCs maturation overnight. After mat-
uration, the cells were detached from the plate using trisodium cit-
rate and gentle pipetting. HLA-DR and HLA-DQ peptide com-
plexes were purified using a modification of a previously
described protocol.23 Briefly, cells were resuspended in 500 mL lysis
buffer containing 10 mM Tris-HCl (pH 8.0), 0.25% octyl-b-D-glu-
copyranoside, 1% sodium deoxycholate and Halt Protease and
Phosphatase Inhibitor Cocktail (Thermo Scientific), and incubated
at 4°C for 30 minutes (mins). The lysed cells were centrifuged at
20,000xg for 15 mins at 4°C. HLA-DR and HLA-DQ peptide com-
plexes were purified from the supernatant by adding L243 or SPV-
L3 coupled CNBr Sepharose, respectively, and incubating the
tubes at 4°C overnight ‘end-over-end’, using a laboratory rotator.
L243 or SPV-L3 Sepharose beads were then washed 2 times with
lysis buffer and 5 times with 10 mM Tris-HCl (pH 8.0). HLA-pep-
tide complexes were eluted using 500 mL 10% acetic acid for 10
mins at room temperature. Then the samples were centrifuged at
400xg for five mins at room temperature and the supernatant
transferred to low-binding 1.5 mL Eppendorf tubes and heated for
15 mins at 70°C. Samples were desalted using C18 STAGE Tips
(Dr. Maisch Gmbh, Amersfoort, the Netherlands).24 STAGE Tips
were eluted with 60 mL of 1% formic acid/30% acetonitrile and
eluates were concentrated using a SpeedVac (Savant, SPP1110,
Thermo Scientific) to a final volume of 5 mL.
Mass spectrometry data analysis
Raw data files from the Orbitrap Fusion Tribid were scored
against the uniprot-organism_9606_AND_keyword_kw_0181
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database using Proteome Discover 1.4 (Thermo Scientific) with a
20 ppm tolerance for precursor mass and 10 ppm tolerance for
fragment mass. Oxidation (+15.995 Da) on methionine was select-
ed as dynamic modification. A decoy database comprising the
reverse protein sequences from the same database was used to
obtain a false discovery rate (FDR). Only peptides with a high or
medium confidence (FDR threshold 0.05%) were considered for
protein scoring.
Results
Presentation of ADAMTS13-derived peptides 
on HLA-DQ
To assess the contribution of HLA-DQ to the presenta-
tion of ADAMTS13-derived peptides, we pulsed mo-DCs
from a panel of 9 HLA-typed healthy donors with 100 nM
ADAMTS13. The HLA type of the donors included in this
study is shown in Table 1. Mo-DCs from the same panel
of donors were recently analyzed for the presentation of
FVIII-derived peptides on HLA-DQ.25 Mo-DCs were incu-
bated with 1 mg/mL LPS and 1% fetal calf serum to allow
for their maturation. HLA-DR and HLA-DQ molecules
were purified employing monoclonal antibodies directed
against HLA-DR (L243) and HLA-DQ (SPV-L3),22 and the
eluates were analyzed by mass-spectrometry. In agree-
ment with our previous reports,19,23,25 peptides derived
from endogenously expressed as well as internalized pro-
teins were presented on HLA-DR and HLA-DQ (Online
Supplementary Table S1A and B, respectively). A subset of
peptides was derived from proteins that are found within
the endolysosomal compartment; these include HLA-DR
itself, several proteases (such as cathepsin B) and endocyt-
ic receptors (such as the macrophage mannose receptor
and prolow-density lipoprotein receptor-related protein
1).
The total number of unique peptides that was identified
in the pulldowns of HLA-DR and HLA-DQ is shown in
Figure 1A and Online Supplementary Figure S1. The total
number of peptides presented on HLA-DQ was approxi-
mately 3-fold lower when compared to HLA-DR (median
of 566 unique peptides on HLA-DQ compared to 1521 on
HLA-DR). Similarly, although not statistically significant,
the number of ADAMTS13-derived peptides presented on
HLA-DQ was 3-fold lower when compared to HLA-DR
(Figure 1B). HLA-DR-presented ADAMTS13-derived pep-
tides were identified for all donors whereas ADAMTS13-
derived peptides presented on HLA-DQ were only found
in 4 out of 9 donors (Table 2A and B, and Online
Supplementary Figure S1B).
Repertoire of ADAMTS13-derived peptides presented
on HLA-DR
In order to compare the repertoire of ADAMTS13-
derived peptides presented on HLA-DR and HLA-DQ, the
binding cores of the ADAMTS13-derived unique peptides
were predicted using the NetMHCIIpan 3.1 software
(Table 2A and B).26 ADAMTS13-derived peptides that
shared the same core sequence were grouped (Figure 2).
Previously, we have shown that ADAMTS13-derived pep-
tides containing the sequence FINVAPHAR were present-
ed on HLA-DRB1*11.19 Peptides sharing the same
sequence were also presented on non-HLA-DRB1*11 pos-
itive donors when mo-DCs were pulsed with 500 nM of
ADAMTS13.19 In the current study, peptides containing
the FINVAPHAR sequence were presented on mo-DCs of
HLA-DRB1*11 positive donors 7 and 8. Peptides with
core-sequence FINVAPHAR were also presented by mo-
DCs derived of HLA-DRB1*11 negative donors 1 and 9
(Table 2A). However, no peptides containing the FIN-
VAPHAR sequence were identified in HLA-DRB1*11 pos-
itive donor 6 (Table 2A). Peptides derived from the
sequence IHALATNMG which is located adjacent to the
FINVAPHAR peptide were found in DRB1*11 negative
donor 2 (Table 2A). Peptides derived from sequence
LIRDTHSLR were identified in DRB1*03 positive donor 9.
In a previous study, LIRDTHSLR-derived peptides were
also presented by mo-DCs derived of DRB1*03 positive
donors.19 It is noteworthy that donors 6 and 7 with the
same HLA-DRB1 haplotype (DRB1*01:01/DRB1*11:01)
both presented peptides derived of core sequence LKTLP-
PARC originating from the TSP3 domain of ADAMTS13
(Table 2A). The majority of the HLA-DR-presented pep-
tides identified in this study were derived from the CUB
domains (Table 2A and Figure 2).
HLA-DQ contributes to presentation of 
ADAMTS13-derived peptides
We found ADAMTS13-derived peptides associated
with HLA-DQ in 4 out of 9 donors (Table 2B and Figure
2). We identified 4 sets of peptides that were exclusively
presented by HLA-DQ that originated from the cysteine-
rich, TSP2, and TSP2-linker 1 of ADAMTS13 (Figure 2).
This suggests that the repertoire of peptides presented on
HLA-DQ differs from that presented on HLA-DR. We also
identified peptides that were presented both on HLA-DR
Presentation of ADAMTS13 peptides on HLA-DR and HLA-DQ
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Table 1. MHC-II genotype of healthy donors included in the study. The donors included in this study were typed for HLA-DRB1/DQB1 using PCR-
SBT and HLA-DQA1 using next generation sequencing workflow.
Donor HLA-DRB1 HLA-DQA1 HLA-DQB1
1 07:01 14:54 01:04 02:01 03:03 05:03
2 04:04 15:01 01:02 03:01 03:02 06:02
3 01:01 15:01 01:01 04:01 05:01 06:02
4 01:01 08:01 01:01 04:01 04:02 05:01
5 01:01 07:01 01:01 02:01 02:02 05:01
6 01:01 11:01 01:01 05:05 03:01 05:01
7 01:01 11:01 01:01 05:05 03:01 05:01
8 04:01 11:01 03:01 05:05 03:01 03:02
9 03:01 13:01 01:01 05:01 02:01 06:03
and HLA-DQ. This is exemplified by the peptide derived
from the CUB1 domain of ADAMTS13, spanning amino
acid sequence 1206-1222 – RGPGQADCAVAIGRPLG,
that was identified on both HLA-DR and HLA-DQ of
donors 2 and 3 (Figure 2). However, in the case of donor 9
this peptide was found on HLA-DQ but not on HLA-DR.
Similarly, two peptides derived from the metalloprotease
and CUB2 domains of ADAMTS13 were identified both
on HLA-DR and HLA-DQ for donors 8 and 9, respectively.
Our data show that, while HLA-DQ is involved in
ADAMTS13, HLA-DR is more likely to be presenting pep-
tides from ADAMTS13, and that there is considerable
overlap between the repertoires of ADAMTS13-derived
peptides presented on HLA-DR and HLA-DQ. 
Evaluation of ADAMTS13 peptide immunogenicity using
bioinformatic approaches
The above findings document which ADAMTS13 pep-
J. Hrdinová et al.
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Figure 1. Relative presentation of total peptides and ADAMTS13-
derived peptides on HLA-DR and HLA-DQ. (A) Total number of
peptides identified after elution from either HLA-DR or HLA-DQ. (B)
The ADAMTS13-derived peptides found on either HLA-DR or HLA-
DQ. Statistical differences in peptide presentation were deter-
mined using the non-parametric Mann-Whitney U-test. **P<0.01.
ns: not significant. 
Figure 2. ADAMTS13-derived peptides presented on HLA-DR and HLA-DQ. Peptides identified to be presented by DCs of 9 studied donors on HLA-DR and HLA-DQ.
Longest amino acid sequence of overlapping peptides is shown in the third column. Amino acids that are predicted to be a part of the peptide-MHC-II binding core
are shown in bold. Blue: peptides identified only in HLA-DR condition. Red: peptides identified exclusively in HLA-DQ condition. Green: peptides identified in both
HLA-DR and HLA-DQ conditions. 
A
B
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Table 2. HLA-DRB1 and HLA-DQA1/DQB1 peptide presentation and core-peptide binding affinity prediction. The ADAMTS13-derived peptides
identified for each donor were analyzed for their binding affinities to the donor specific HLA-DRB1 (A) or HLA-DQA1/HLA-DQB1 alleles (B) using
the NetMHCIIpan 3.1 software. The affinity value is presented in nM. For each peptide, a binding core was predicted. Binding cores with the high-
est affinity to the particular MHC-II are shown in yellow. Right panel represents the domain origin of each peptide.  
A
tides are displayed on MHC class II following pulsing of
dendritic cells with ADAMTS13. To complement our
analysis of peptides eluted from MHC, we employed a
bio-informatic approach to identify whether the
ADAMTS13-derived peptides identified in this and a pre-
vious study (Table 3)19 might be immunogenic. Firstly, we
used the EpiMatrix algorithm, which assesses the poten-
tial for individual peptides to bind to HLA-DR based on
amino acid motifs preferred by nine “supertype” HLA-DR
allele families. These HLA-DR motif families cover 95%
of the human population worldwide.27 EpiMatrix assesses
peptides for binding potential against a matrix of amino
acid preferences for each HLA allele. This score is adjusted
to a normalized (Z) score. The EpiMatrix Score of a pep-
tide represents a sum of significant assessments for all of
the nine-mers in a sequence, adjusted for length. An
EpiMatrix Score of 40.66 was obtained for metallo-pro-
tease-derived peptide SRRQLLSLLSAGRAR (residues 266-
280); this value indicates that this peptide has a significant
potential to bind to multiple HLA-DR molecules (Table 3).
Also, the CUB2 domain-derived peptide FSEGFLKA-
QASLRGQYW (residues 1390-1406) was predicted to
bind to multiple HLA-DR alleles (Table 3). A number of
other CUB1-2 domain-derived peptides were found to be
potentially immunogenic, as revealed by an EpiMatrix
Score higher than 10 (Table 3). 
A second tool, JanusMatrix,28 was used to evaluate
whether the HLA-DR-presented ADAMTS13 peptides dis-
played homology to proteins from the human proteome.
JanusMatrix differentiates HLA-binding peptides that are
more cross-conserved at the TCR face and thus more likely
tolerated (or actively tolerogenic) from those less cross-con-
served that are more likely to be immunogenic.29,30 This
analysis revealed that six of the peptides (Table 3 and
J. Hrdinová et al.
1088 haematologica | 2018; 103(6)
B
Figure 3) showed promiscuity in binding to supertype HLA-
DR alleles in combination with low cross-conservation
with human proteins. These peptides could potentially ini-
tiate an effector T-cell response. In contrast, four of the pep-
tides (Table 3 and  Figure 3) were found to be cross-con-
served within the human protein repertoire and could thus
be potentially tolerated or actively tolerogenic in patients
with acquired TTP. The remaining 10 ADAMTS13 peptides
did not register high EpiMatrix Scores for binding to HLA-
DR. However, they did have significant assessments for
individual HLA-DR alleles and therefore could be presented
on a subset of MHC II molecules. 
Discussion
In this study, we explored the repertoire of HLA-DQ-
presented peptides on ADAMTS13 pulsed monocyte-
derived dendritic cells. In parallel, we also assessed the
HLA-DR-presented peptide repertoire. This approach
allows for a direct comparison of the peptide repertoires
presented on HLA-DR and HLA-DQ. For this, we used
two different monoclonal antibodies, L243 and SPV-L3,
that had been previously used for peptide presentation
profiling on either HLA-DR or HLA-DQ.19,23,31-33 Our data
revealed that the number of peptides presented on HLA-
DQ is 2- to 3-fold lower when compared to the repertoire
presented on HLA-DR. This is most likely explained by
the higher expression of HLA-DR on dendritic cells when
compared to HLA-DQ.25,34,35 Furthermore, this could also
result from an overall lower binding affinity of peptides
for HLA-DQ when compared to HLA-DR. Indeed, the
NetMHCIIpan3.1 prediction tool suggests a higher bind-
ing affinity of ADAMTS13-derived peptides to HLA-DR
when compared to HLA-DQ. In a recent study, we also
observed preferential presentation of blood coagulation
FVIII-derived peptides on HLA-DR when compared to
HLA-DQ.25
Interestingly, using higher-energy collisional dissocia-
tion fragmentation, the total number of peptides identi-
fied in HLA-DR eluates ranged from 1115 to 2247. This
represents a 5- to 6-fold increase when compared to a pre-
vious study from our group that employed collision-
induced dissociation.19 We anticipate that the use of a
highly sensitive mass spectrometer (Orbitrap Fusion
Tribrid) has allowed for an increased number of peptides
identified on HLA-DR. Surprisingly, despite the use of a
highly sensitive mass-spectrometry strategy, the number
of ADAMTS13-derived peptides remained relatively low
in the case of HLA-DR and even lower for HLA-DQ (an
average of 7 vs. 3 ADAMTS13-derived peptides, respec-
tively). In the current study, we pulsed mo-DCs with 100
nM of recombinant ADAMTS13, whereas circulating lev-
els of ADAMTS13 in healthy individuals ranges from 3.5-
7 nM (740-1420 ng/mL).36 Previous work from our group
has identified the mannose receptor as an endocytic recep-
tor for ADAMTS13 by mo-DCs.37 More recently, we
described the involvement of CD163 in the internalization
of ADAMTS13 by macrophages in vitro.38 In the latter
study, we observed that the uptake efficiency of CD163-
positive macrophages was approximately 10 times higher
when compared to that of mo-DCs (that are devoid of
CD163 expression). Based on this finding, it is tempting to
speculate that the limited presentation of ADAMTS13-
derived peptides on mo-DCs is due to a relatively low effi-
ciency to internalize ADAMTS13, thereby limiting the
number of ADAMTS13-derived peptides that are present-
ed. Whether the limited presentation of ADAMTS13 by
dendritic cells explains the low incidence of TTP in the
general population despite the high prevalence of the risk
Presentation of ADAMTS13 peptides on HLA-DR and HLA-DQ
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Figure 3. Schematic representation of eluted peptide immunogenicity. EpiMatrix and JanusMatrix Homology Scores for each eluted peptide is depicted in the graph.
In the context of nine population-spanning “supertype” HLA-DR alleles, peptides with high (>10, orange) EpiMatrix Score are predicted to be promiscuous epitopes,
presented by multiple HLA-DR alleles. Additionally, peptides with elevated to high (>3) JanusMatrix Homology Scores display high homology with human proteome
at the TCR face and are predicted to be tolerated or actively tolerogenic (green squares). Peptides with high EpiMatrix Score (>10) in combination with low
JanusMatrix Homology Score (<3) are predicted to be immunogenic (red squares). All other peptides, with an EpiMatrix Score <10, have limited or HLA-restricted
immunogenic potential (black squares). 
alleles HLA-DRB1*11 and DQB1*03 in the general popu-
lation represents an interesting question that needs further
study.
The overall low number of ADAMTS13-derived pep-
tides reported may also be due to post-translational mod-
ifications of HLA-DR/DQ-presented peptides that inter-
fere with their identification. For instance, the presence of
a glycan results in a shift in the net mass of the glycan-
bearing peptide, impairing its identification by mass spec-
trometry. Ten N-glycosylation sites, 8 O-fucosylation sites
and 3 C-mannosylation sites have been described for plas-
ma-derived ADAMTS13.39,40 As yet, the impact of post-
translational modifications such as N-linked glycosylation
on MHC-II peptide presentation has not been extensively
studied. To our surprise, we also identified a peptide
derived from the TSP2 domain of ADAMTS13
(NYSCLDQAR) that has been reported to contain an N-
linked glycosylation site.39 A recent publication from our
group showed that the asparagine present within this pep-
tide contains a bi-antennary complex-glycan.40 As men-
tioned earlier, the presence of a glycan interferes with the
identification of the glycan-bearing peptide by mass spec-
trometry. However, it was previously described that the
third position in peptides with consensus sequence Asn-
X-Ser/Thr affects glycosylation efficiency, Thr being asso-
ciated with a higher degree of glycosylation compared to
Ser.41 It is, therefore, likely that the identified peptide
NYSCLDQAR is partially glycosylated, allowing for the
identification of the non-glycosylated version in our study.
Whether the glycosylated counterpart of this peptide is
also presented on HLA molecules remains to be deter-
mined. How the presence or absence of an N-linked gly-
can at this position modulates peptide/MHC-II/T-cell
receptor (TCR) binding represents an interesting question.
On one hand, the presence of an N-linked glycan at this
position could interfere with the binding of the peptides
to HLA-DQ or with the recognition of the HLA-DQ/pep-
tide complex by a complementary T-cell receptor (TCR).
Interestingly, absence of an O-linked glycan on type II col-
lagen has been previously suggested to create a novel T-
cell epitope that has been implicated in the development
of autoimmune arthritis.42-44 Similarly, CD4+ T cells recog-
nizing non-glycosylated forms of ADAMTS13-derived
peptides that normally contain a glycan may contribute to
the onset of autoimmune TTP. On the other hand,  the
presence of a glycan can also lead to the formation of a
neo-epitope.45 In view of the large number of N-and O-
linked glycans on ADAMTS13, it cannot be excluded that
J. Hrdinová et al.
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Table 3. Evaluation of ADAMTS13 peptide immunogenicity in silico. 
Binding of peptides to nine common HLA-DR allele families was predicted using the EpiMatrix algorithm developed by EpiVax. An EpiMatrix Score that reflects peptide binding
potential to each of the 9 HLA-DR alleles was assigned to each peptide. Peptides with EpiMatrix scores  > 5 are predicted to have elevated immunogenic potential; peptides with
scores > 10 are predicted to have significant immunogenic potential. In addition, JanusMatrix was used to predict potential cross-reactivity between the peptides and the human
proteome, based on conservation of TCR-facing residues. A JanusMatrix Homology Score was assigned to each peptide. Higher scores indicate greater conservation with the
human proteome. At the population level, given elevated to high EpiMatrix scores, peptides with low cross-conservation with human proteome (scores < 3) are considered likely
to be immunogenic, while peptides with scores  > 3 have elevated to high cross-conservation with human proteome and are thus potentially tolerated or tolerogenic.
glycan-containing peptides derived of ADAMTS13 are
presented on MHC-II.40
Identification of the immunogenic determinants of
ADAMTS13 represents a major challenge for the under-
standing of TTP pathogenesis. Our study shows that there
is an overlap, but also differences, in the repertoire of
ADAMTS13-derived peptides that are presented on HLA-
DQ and HLA-DR. This is illustrated by the peptide with
core sequence FINVAPHAR derived from the CUB2
domain that was identified exclusively in the case of 
HLA-DR. In contrast with the study of Sorvillo et al., only
2 out of the 3 HLA-DRB1*11 donors presented the FIN-
VAPHAR peptide. In addition, this peptide was also iden-
tified in 2 non-HLA-DRB1*11 donors, confirming that the
presentation of FINVAPHAR is not restricted to HLA-
DRB1*11.19 Interestingly, several peptides were identified
associated with HLA-DQ only. Especially, two peptides
derived from the cysteine-rich domain were identified
exclusively on HLA-DQ. Lastly, we identified sets of pep-
tides that were presented on both HLA-DR and HLA-DQ,
as exemplified by the CUB1-derived peptide with core-
sequence CAVAIGRPL.
Whether the novel peptides identified in this study play
a role in the onset of acquired TTP remains to be deter-
mined. A previous study of Verbij et al. showed that CUB2
domain-derived peptides FINVAPHAR and ASYILIRD are
able to activate CD4+ T cells from an HLA-DRB1*11 and
an HLA-DRB1*03-positive acquired TTP patient, respec-
tively.20 A recent study by Gilardin et al. did not identify
CD4+ T cells responding to peptide ADAMTS131239-1253 con-
taining the FINVAPHAR core-sequence in HLA-DRB1*11-
positive patients.21 In their hands, another CUB2 domain-
derived peptide ADAMTS131239-1253 was identified as an
immunodominant T-cell epitope for both DRB1*01 and
DRB1*11-positive acquired TTP patients.21 Surprisingly,
the ADAMTS131239-1253 peptide was not identified to be
presented on HLA-DR or DQ in our current study, despite
the fact that several HLA-DRB1*01 and HLA-DRB1*11
positive donors were included in our cohort. Two pep-
tides containing the same core-sequence were, however,
identified in a DRB1*0401/DRB1*1301 positive donor in a
previous study from our group.19
In silico approaches (EpiMatrix) identified a majority of
ADAMTS13 peptides (70%) with significant EpiMatrix
scores in the CUB1/2 domains. Six of the eluted
ADAMTS13 peptides with low cross-conservation with
the human proteome (based on JanusMatrix analysis)
were considered to be more likely to elicit an effector T-
cell response. These predicted immunogenic peptide
sequences included ADAMTS131322-1341 (FINVAPHAR) and
ADAMTS131355-1373 (ASYILIRD); CD4+ T cells targeting
these epitopes have indeed been found in patients with
acquired TTP.20 In contrast, four of the peptides had TCR
facing residues that were highly conserved with multiple
peptides found in the human proteome and putatively
restricted by the same HLA, and, therefore, could poten-
tially be tolerated or actively tolerogenic in patients with
acquired TTP. These peptides include peptide
ADAMTS131238-1252, containing a minimal core sequence
recognized by the ADAMTS13-specific DRB1*01:01-
restricted T-cell hybridomas as described by Gilardin et
al.21 CD4+ T cells targeting different epitopes may develop
in patients with acquired TTP. Phenotypic profiling of
CD4+ T-cell responses in large numbers of patients with
acquired TTP will be needed to define whether multiple
immune-dominant and potential immunoregulatory
CD4+ T-cell epitopes contribute to the etiology of
acquired TTP. 
Acknowledgments
The authors would like to thank Erik Mul and Mark
Hoogeboezem for elutriation of the buffy coats. We are grateful to
William Martin and Frances Terry (EpiVax) for their help with
the in silico data analysis. 
Funding
This study was supported by grants from the Landsteiner
Foundation of Blood Transfusion Research and Horizon 2020
Framework Programme for Research and Innovation of the
European Union (Grant Agreement No. 675746).
Presentation of ADAMTS13 peptides on HLA-DR and HLA-DQ
haematologica | 2018; 103(6) 1091
References
1. Zheng X, Majerus EM, Sadler JE.
ADAMTS13 and TTP. Curr Opin Hematol.
2002;9(5):389-394.
2. Kremer Hovinga JA, Coppo P, Lämmle B,
Moake JL, Miyata T, Vanhoorelbeke K.
Thrombotic thrombocytopenic purpura.
Nat Rev Dis Prim. 2017;3:17020.
3. George JN. Clinical practice. Thrombotic
thrombocytopenic purpura. N Engl J Med.
2006;354(18):1927-1935.
4. Ferrari S, Palavra K, Gruber B, et al.
Persistence of circulating ADAMTS13-spe-




5. Ferrari S, Mudde GC, Rieger M, Veyradier
A, Kremer Hovinga JA, Scheiflinger F. IgG
subclass distribution of anti-ADAMTS13
antibodies in patients with acquired throm-
botic thrombocytopenic purpura. J Thromb
Haemost. 2009;7(10):1703-1710.
6. Pos W, Luken BM, Sorvillo N, Kremer
Hovinga JA, Voorberg J. Humoral immune
response to ADAMTS13 in acquired
thrombotic thrombocytopenic purpura. J
Thromb Haemost. 2011;9(7):1285-1291.
7. Long Zheng X, Wu HM, Shang D, et al.
Multiple domains of ADAMTS13 are tar-
geted by autoantibodies against
ADAMTS13 in patients with acquired idio-
pathic thrombotic thrombocytopenic pur-
pura. Haematologica. 2010;95(9):1555-
1562.
8. Luken BM, Kaijen PH, Turenhout EA, et al.
Multiple B-cell clones producing antibodies
directed to the spacer and disintegrin/
thrombospondin type-1 repeat 1 (TSP1) of
ADAMTS13 in a patient with acquired
thrombotic thrombocytopenic purpura. J
Thromb Haemost. 2006;4(11):2355-2364.
9. Pos W, Crawley JT, Fijnheer R, Voorberg J,
Lane DA, Luken BM. An autoantibody epi-
tope comprising residues R660, Y661, and
Y665 in the ADAMTS13 spacer domain
identifies a binding site for the A2 domain
of VWF. Blood. 2010;115(8):1640-1649.
10. Gerth J, Schleussner E, Kentouche K, Busch
M, Seifert M, Wolf G. Pregnancy-associat-
ed thrombotic thrombocytopenic purpura.
Thromb Haemost. 2009;101(2):248-251.
11. Kosugi N, Tsurutani Y, Isonishi A, Hori Y,
Matsumoto M, Fujimura Y. Influenza A
infection triggers thrombotic thrombocy-
topenic purpura by producing the anti-
ADAMTS13 IgG inhibitor. Intern Med.
2010;49(7):689-693.
12. Erdem F, Kiki I, Gundo du M, Kaya H.
Thrombotic thrombocytopenic purpura in
a patient with Brucella infection is highly
responsive to combined plasma infusion
and antimicrobial therapy. Med Princ Pract.
2007;16(4):324-326.
13. Schlienger K, Craighead N, Lee KP, Levine
BL, June CH. Efficient priming of protein
antigen-specific human CD4(+) T cells by
monocyte-derived dendritic cells. Blood.
2000;96(10):3490-3498.
14. Trowsdale J, Knight JC. Major histocom-
patibility complex genomics and human
disease. Annu Rev Genomics Hum Genet.
2013;14:301-323.
15. Coppo P, Busson M, Veyradier A, et al.
HLA-DRB1*11: a strong risk factor for
acquired severe ADAMTS13 deficiency-
related idiopathic thrombotic thrombocy-
topenic purpura in Caucasians. J Thromb
Haemost. 2010;8(4):856-859.
16. Scully M, Brown J, Patel R, Mcdonald V,
Brown CJ, Machin S. Human leukocyte
antigen association in idiopathic thrombot-
ic thrombocytopenic purpura: Evidence for
an immunogenetic link. J Thromb
Haemost. 2010;8(2):257-262.
17. John M-LL, Hitzler W, Scharrer I. The role
of human leukocyte antigens as predispos-
ing and/or protective factors in patients
with idiopathic thrombotic thrombocy-
topenic purpura. Ann Hematol. 2012;91(4):
507-510.
18. Mancini I, Ricaño-Ponce I, Pappalardo E, et
al. Immunochip analysis identifies novel
susceptibility loci in the human leukocyte
antigen region for acquired thrombotic
thrombocytopenic purpura. J Thromb
Haemost. 2016;14(12):2356-2367.
19. Sorvillo N, van Haren SD, Kaijen PHP, et al.
Preferential HLA-DRB1*11-dependent
presentation of CUB2-derived peptides by
ADAMTS13-pulsed dendritic cells. Blood.
2013;121(17):3502-3510.
20. Verbij FC, Turksma AW, de Heij F, et al.
CD4+ T cells from patients with acquired
thrombotic thrombocytopenic purpura rec-
ognize CUB-2 domain derived peptides.
Blood. 2016;127(12):1606-1609.
21. Gilardin L, Delignat S, Peyron I, et al. The
ADAMTS13(1239-1253) peptide is a domi-
nant HLA-DR1-restricted CD4+ T-cell epi-
tope. Haematologica. 2017;102(11):1833-
1841.
22. Spits H, Keizer G, Borst J, Terhorst C,
Hekman A, de Vries JE. Characterization of
monoclonal antibodies against cell surface
molecules associated with cytotoxic activi-
ty of natural and activated killer cells and
cloned CTL lines. Hybridoma.  1983;
2(4):423-437.
23. van Haren SD, Herczenik E, ten Brinke A,
Mertens K, Voorberg J, Meijer AB. HLA-
DR-presented Peptide Repertoires Derived
From Human Monocyte-derived Dendritic
Cells Pulsed With Blood Coagulation Factor
VIII. Mol Cell Proteomics 2011;
10(6):M110.002246.
24. Rappsilber J, Ishihama Y, Mann M. Stop and
go extraction tips for matrix-assisted laser
desorption/ionization, nanoelectrospray,
and LC/MS sample pretreatment in pro-
teomics. Anal Chem. 2003;75(3):663-670.
25. Peyron I, Hartholt RB, Pedró-Cos L, et al.
Comparative profiling of HLA-DR and
HLA-DQ associated factor VIII peptides
presented by monocyte-derived dendritic
cells. Haematologica. 2018;103(1):172-178.
26. Karosiene E, Rasmussen M, Blicher T, Lund
O, Buus S, Nielsen M. NetMHCIIpan-3.0, a
common pan-specific MHC class II predic-
tion method including all three human
MHC class II isotypes, HLA-DR, HLA-DP
and HLA-DQ. Immunogenetics. 2013;
65(10):711-724.
27. De Groot AS, Martin W. Reducing risk,
improving outcomes: bioengineering less
immunogenic protein therapeutics. Clin
Immunol. 2009;131(2):189-201.
28. Moise L, Gutierrez AH, Bailey-Kellogg C,
et al. The two-faced T cell epitope. Hum
Vaccin Immunother. 2013;9(7):1577-1586.
29. Liu R, Moise L, Tassone R, et al. H7N9 T-
cell epitopes that mimic human sequences
are less immunogenic and may induce
Treg-mediated tolerance. Hum Vaccin
Immunother. 2015;11(9):2241-2252.
30. Losikoff PT, Mishra S, Terry F, et al. HCV
epitope, homologous to multiple human
protein sequences, induces a regulatory T
cell response in infected patients. J Hepatol.
2015;62(1):48-55.
31. de Verteuil D, Muratore-Schroeder TL,
Granados DP, et al. Deletion of immuno-
proteasome subunits imprints on the tran-
scriptome and has a broad impact on pep-
tides presented by major histocompatibili-
ty complex I molecules. Mol Cell
Proteomics. 2010;9(9):2034-2047.
32. Wahlström J, Dengjel J, Persson B, et al.
Identification of HLA-DR-bound peptides
presented by human bronchoalveolar
lavage cells in sarcoidosis. J Clin Invest.
2007;117(11):3576-3582.
33. Fissolo N, Haag S, de Graaf KL, et al.
Naturally presented peptides on major his-
tocompatibility complex I and II molecules
eluted from central nervous system of mul-
tiple sclerosis patients. Mol Cell
Proteomics. 2009;8(9):2090-2101.
34. Brooks CF, Moore M. Differential MHC
class II expression on human peripheral
blood monocytes and dendritic cells.
Immunology. 1988;63(2):303-311.
35. Fernandez S, Wassmuth R, Knerr I, Frank
C, Haas JP. Relative quantification of HLA-
DRA1 and -DQA1 expression by real-time
reverse transcriptase-polymerase chain
reaction (RT-PCR). Eur J Immunogenet.
2003;30(2):141-148.
36. Rieger M, Ferrari S, Kremer Hovinga JA, et
al. Relation between ADAMTS13 activity
and ADAMTS13 antigen levels in healthy
donors  and patients with thrombotic
microangiopathies (TMA). Thromb
Haemost. 2006;95(2):212-220.
37. Sorvillo N, Pos W, van den Berg LM, et al.
The macrophage mannose receptor pro-
motes uptake of ADAMTS13 by dendritic
cells. Blood. 2012;119(16):3828-3835.
38. Verbij FC, Sorvillo N, Kaijen PHP, et al. The
class I scavenger receptor CD163 promotes
internalization of ADAMTS13 by
macrophages. Blood Adv. 2017;1(5):293-
305.
39. Sorvillo N, Kaijen PHP, Matsumoto M, et al.
Identification of N-linked glycosylation and
putative O-fucosylation, C-mannosylation
sites in plasma derived ADAMTS13. J
Thromb Haemost. 2014;12(5):670-679.
40. Verbij FC, Stokhuijzen E, Kaijen PHP, van
Alphen F, Meijer AB, Voorberg J.
Identification of glycans on plasma-derived
ADAMTS13. Blood. 2016;128(21):e51-e58.
41. Nicolaes GAF, Villoutreix BO, Dahlbäck B.
Partial glycosylation of Asn2181 in human
factor V as a cause of molecular and func-
tional heterogeneity. Modulation of glyco-
sylation efficiency by mutagenesis of the
consensus sequence for N-linked glycosyla-
tion. Biochemistry. 1999;38(41):13584-
13591.
42. Enouz S, Carrié L, Merkler D, Bevan MJ,
Zehn D. Autoreactive T cells bypass nega-
tive selection and respond to self-antigen
stimulation during infection. J Exp Med.
2012;209(10):1769-1779.
43. Dzhambazov B, Holmdahl M, Yamada H, et
al. The major T cell epitope on type II colla-
gen is glycosylated in normal cartilage but
modified by arthritis in both rats and
humans. Eur J Immunol. 2005;35(2):357-366.
44. Yamada H, Dzhambazov B, Bockermann
R, Blom T, Holmdahl R. A transient post-
translationally modified form of cartilage
type II collagen is ignored by self-reactive T
cells. J Immunol. 2004;173(7):4729-4735.
45. Purcell AW, van Driel IR, Gleeson PA.
Impact of glycans on T-cell tolerance to gly-
cosylated self-antigens. Immunol Cell Biol.
2008;86(7):574-579.
J. Hrdinová et al.
1092 haematologica | 2018; 103(6)
